The importance of capital cannot be ignored in a field like research where scientists keep digging into the subject matter until they find an optimal solution. Amongst many other companies, Propanc Health Group Corp (OTCMKTS:PPCH) shares an acknowledgeable place in the healthcare field. It recently announced that it had raised capital to execute its next round of animal studies.
Insights On Matter:
Propanc is considered as one of the fastest growing healthcare companies in today’s time. It has been focusing on running proprietary treatments for patients suffering from cancer for a long time. Propanc was in need of money and trying to get any long term investor on board lately. Finally, it has succeeded in acquiring an institutional investor.
As per the reports, Propanc has raised over $468,500 recently. It’s not over as it has also received commitments from various other investors as well. The company is expecting another $532,500 in the near future. The complete funding that it has got will be used to finish its next round of animal studies, which are very important for the company to start trials on humans.
So far, it hasn’t tried its drug on humans, but the management of Propanc is optimistic that it will complete the animal trials and start human trials very soon. Once it shows successful results, then only can it have further discussions in regard with its sought after product, PRP.
The senior management of the healthcare company is cocksure sure that these studies will have a positive impact on humans. According to Dr. Julian Kenyon, Chief Scientific Officer, Propanc Health Group Corp (OTCMKTS:PPCH), the company is trying to investigate I.V administration of PRP, which is believed to be way more effective on cancer tumors than other similar drugs. He stated that Propanc would notify investors as soon as it finishes its animal trials.